Sandbox ID Genitourinary: Difference between revisions

Jump to navigation Jump to search
Line 62: Line 62:


* [[Neisseria gonorrhoeae|''Neisseria gonorrhoeae'' infection]]<ref>{{Cite journal| issn = 1545-8601| volume = 59| issue = RR-12| pages = 1–110| last1 = Workowski| first1 = Kimberly A.| last2 = Berman| first2 = Stuart| last3 = Centers for Disease Control and Prevention (CDC)| title = Sexually transmitted diseases treatment guidelines, 2010| journal = MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control| date = 2010-12-17| pmid = 21160459}}</ref><ref>{{Cite journal| issn = 1545-861X| volume = 61| issue = 31| pages = 590–594| last = Centers for Disease Control and Prevention (CDC)| title = Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections| journal = MMWR. Morbidity and mortality weekly report| date = 2012-08-10| pmid = 22874837}}</ref>
* [[Neisseria gonorrhoeae|''Neisseria gonorrhoeae'' infection]]<ref>{{Cite journal| issn = 1545-8601| volume = 59| issue = RR-12| pages = 1–110| last1 = Workowski| first1 = Kimberly A.| last2 = Berman| first2 = Stuart| last3 = Centers for Disease Control and Prevention (CDC)| title = Sexually transmitted diseases treatment guidelines, 2010| journal = MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control| date = 2010-12-17| pmid = 21160459}}</ref><ref>{{Cite journal| issn = 1545-861X| volume = 61| issue = 31| pages = 590–594| last = Centers for Disease Control and Prevention (CDC)| title = Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections| journal = MMWR. Morbidity and mortality weekly report| date = 2012-08-10| pmid = 22874837}}</ref>
:* '''Uncomplicated Gonococcal Infections of the Cervix, Urethra, and Rectum'''
:* '''Uncomplicated gonococcal infections of the cervix, urethra, and rectum'''
::* Preferred regimen: [[Ceftriaxone]] 250 mg IM as a single dose {{and}} ([[Azithromycin]] 1 g PO as a single dose {{or}} [[Doxycycline]] 100 mg PO bid for 7 days)
::* Preferred regimen: [[Ceftriaxone]] 250 mg IM as a single dose {{and}} ([[Azithromycin]] 1 g PO as a single dose {{or}} [[Doxycycline]] 100 mg PO bid for 7 days)
::* Alternative regimen: [[Cefuroxime]] 1 g PO as a single dose
::* Alternative regimen: [[Cefuroxime]] 1 g PO as a single dose


:* '''Uncomplicated Gonococcal Infections of the Pharynx'''
:* '''Uncomplicated gonococcal infections of the pharynx'''
::* Preferred regimen: [[Ceftriaxone]] 250 mg IM in a single dose {{and}} ([[Azithromycin]] 1 g orally as a single dose {{or}} [[Doxycycline]] 100 mg orally twice daily for 7 days)
::* Preferred regimen: [[Ceftriaxone]] 250 mg IM in a single dose {{and}} ([[Azithromycin]] 1 g orally as a single dose {{or}} [[Doxycycline]] 100 mg orally twice daily for 7 days)


:* '''Gonococcal Conjunctivitis'''
:* '''Gonococcal conjunctivitis'''
::* Preferred regimen: [[Ceftriaxone]] 1 g IM in a single dose
::* Preferred regimen: [[Ceftriaxone]] 1 g IM in a single dose


:* '''Disseminated Gonococcal Infection (DGI)'''
:* '''Disseminated gonococcal infection'''
::* Preferred regimen: [[Ceftriaxone]] 1 g IV/IM every 24 hours
::* Preferred regimen: [[Ceftriaxone]] 1 g IV/IM every 24 hours
::* Alternative regimen: [[Cefotaxime]] 1 g IV every 8 hours {{or}} [[Ceftizoxime]] 1 g IV every 8 hours
::* Alternative regimen: [[Cefotaxime]] 1 g IV every 8 hours {{or}} [[Ceftizoxime]] 1 g IV every 8 hours
::: Note: All of the preceding regimens should be continued for 24-48 hours after improvement begins, at which time therapy can be switched to [[Cefixime]] 400 mg PO bid to complete at least 1 week of antimicrobial therapy.
::: Note: All of the preceding regimens should be continued for 24-48 hours after improvement begins, at which time therapy can be switched to [[Cefixime]] 400 mg PO bid to complete at least 1 week of antimicrobial therapy.


:* '''Gonococcal Meningitis '''
:* '''Gonococcal meningitis '''
::* Preferred regimen: [[Ceftriaxone]] 1-2 g IV every 12 hours for 10-14 days
::* Preferred regimen: [[Ceftriaxone]] 1-2 g IV every 12 hours for 10-14 days


:* '''Gonococcal Endocarditis'''
:* '''Gonococcal endocarditis'''
::* Preferred regimen: [[Ceftriaxone]] 1-2 g IV every 12 hours for at least 4 weeks
::* Preferred regimen: [[Ceftriaxone]] 1-2 g IV every 12 hours for at least 4 weeks


:* Gonococcal Infections Among Infants
:* Gonococcal Infections Among Infants
::* '''Ophthalmia Neonatorum Caused by N. gonorrhoeae'''
::* '''Ophthalmia neonatorum'''
:::* Preferred regimen: [[Ceftriaxone]] 25-50 mg/kg IV or IM in a single dose, not to exceed 125 mg
:::* Preferred regimen: [[Ceftriaxone]] 25-50 mg/kg IV or IM in a single dose, not to exceed 125 mg


::* '''DGI and Gonococcal Scalp Abscesses in Newborns'''
::* '''Disseminated gonococcal infection and gonococcal scalp aAbscesses in newborns'''
:::* Preferred regimen:
:::* Preferred regimen:



Revision as of 21:48, 30 May 2015

Asymptomatic bacteriuria

Bacterial vaginosis

Cervicitis

Chancroid

Note (1): Ciprofloxacin is contraindicated for pregnant and lactating women.
Note (2): Patients should be tested for HIV infection at the time chancroid is diagnosed. If the initial test results were negative, a serologic test for syphilis and HIV infection should be performed 3 months after the diagnosis of chancroid.
Note (3): Sex partners of patients who have chancroid should be examined and treated if they had sexual contact with the patient during the 10 days preceding the patient's onset of symptoms.

Chlamydial infections

Chorioamnionitis

Cystitis

Ectoparasitic infections

Epididymitis

Genital herpes

  • First episode of genital herpes
Note: Treatment can be extended if healing is incomplete after 10 days of therapy.
  • Recurrent genital herpes
  • Suppressive therapy
  • Episodic therapy
  • Severe genital herpes
  • Preferred regimen: Acyclovir 5–10 mg/kg IV q8h for 2–7 days or until clinical improvement is observed, followed by PO antiviral therapy to complete at least 10 days of total therapy.
Note (1): Acyclovir dose adjustment is recommended for impaired renal function.
Note (2): Symptomatic sex partners should be evaluated and treated in the same manner as patients who have genital lesions. Asymptomatic sex partners of patients who have genital herpes should be questioned concerning histories of genital lesions and offered type-specific serologic testing for HSV infection.
  • Genital herpes in HIV-infected patients
  • Suppressive therapy
  • Episodic therapy
  • Genital herpes in pregnancy
  • Acyclovir can be administered orally to pregnant women with first episode of genital herpes or recurrent genital herpes.
  • Acyclovir should be administered IV to pregnant women with severe genital herpes.
  • Neonatal herpes
  • Disease limited to the skin and mucous membranes
  • Preferred regimen: Acyclovir 20 mg/kg IV q8h for 14 days
  • Disseminated and CNS disease
  • Preferred regimen: Acyclovir 20 mg/kg IV q8h for 21 days

Gonococcal infections

  • Uncomplicated gonococcal infections of the cervix, urethra, and rectum
  • Uncomplicated gonococcal infections of the pharynx
  • Gonococcal conjunctivitis
  • Disseminated gonococcal infection
Note: All of the preceding regimens should be continued for 24-48 hours after improvement begins, at which time therapy can be switched to Cefixime 400 mg PO bid to complete at least 1 week of antimicrobial therapy.
  • Gonococcal meningitis
  • Preferred regimen: Ceftriaxone 1-2 g IV every 12 hours for 10-14 days
  • Gonococcal endocarditis
  • Preferred regimen: Ceftriaxone 1-2 g IV every 12 hours for at least 4 weeks
  • Gonococcal Infections Among Infants
  • Ophthalmia neonatorum
  • Preferred regimen: Ceftriaxone 25-50 mg/kg IV or IM in a single dose, not to exceed 125 mg
  • Disseminated gonococcal infection and gonococcal scalp aAbscesses in newborns
  • Preferred regimen:

Granuloma Inguinale

Human papillomavirus infection

Lymphogranuloma venereum

Pelvic inflammatory disease

Proctocolitis

Prostatitis, acute bacterial

Prostatitis, chronic bacterial

Pyelonephritis

Syphilis

Urethritis

Vulvovaginal candidiasis


References

  1. Workowski, Kimberly A.; Berman, Stuart; Centers for Disease Control and Prevention (CDC) (2010-12-17). "Sexually transmitted diseases treatment guidelines, 2010". MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 59 (RR-12): 1–110. ISSN 1545-8601. PMID 21160459.
  2. Workowski, Kimberly A.; Berman, Stuart; Centers for Disease Control and Prevention (CDC) (2010-12-17). "Sexually transmitted diseases treatment guidelines, 2010". MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 59 (RR-12): 1–110. ISSN 1545-8601. PMID 21160459.
  3. Workowski, Kimberly A.; Berman, Stuart; Centers for Disease Control and Prevention (CDC) (2010-12-17). "Sexually transmitted diseases treatment guidelines, 2010". MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 59 (RR-12): 1–110. ISSN 1545-8601. PMID 21160459.
  4. Centers for Disease Control and Prevention (CDC) (2012-08-10). "Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections". MMWR. Morbidity and mortality weekly report. 61 (31): 590–594. ISSN 1545-861X. PMID 22874837.